Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in Advanced NSCLC with FGFR Alterations
NCT05210946Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of pemigatinib in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Soochow University. Status: unknown.
02
Drugs
pemigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05210946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05210946.